
CONTENTS

IMPORTANT NOTICE TO INVESTORS

This prospectus is issued by SciClone Pharmaceuticals (Holdings) Limited solely in connection with the Hong Kong Public Offering and the Hong Kong Offer Shares, and does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the Hong Kong Offer Shares offered by this prospectus pursuant to the Hong Kong Public Offering. This prospectus may not be used for the purpose of, and does not constitute, an offer or invitation in any other jurisdiction or in any other circumstances. No action has been taken to permit a public offering of the Offer Shares or the distribution of this prospectus in any jurisdiction other than Hong Kong. The distribution of this prospectus and the offering and sale of the Offer Shares in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom.

You should rely on the information contained in this prospectus and the Application Forms to make your investment decision. We have not authorized anyone to provide you with information that is different from what is contained in this prospectus. Any information or representation not made in this prospectus must not be relied on by you as having been authorized by us, the Joint Sponsors, the Joint Global Coordinators, the Joint Bookrunners, and the Joint Lead Managers, the Underwriters, any of our or their respective directors, officers or representatives or any other person involved in the Global Offering. Information contained in our website, located at www.sciclone.com, does not form part of this prospectus.

EXPECTED TIMETABLE	i
CONTENTS	iv
SUMMARY	1
DEFINITIONS	25
GLOSSARY OF TECHNICAL TERMS	35
FORWARD-LOOKING STATEMENTS	45
RISK FACTORS	47
WAIVERS FROM STRICT COMPLIANCE WITH THE LISTING RULES AND EXEMPTIONS FROM COMPLIANCE WITH THE COMPANIES (WINDING UP AND MISCELLANEOUS PROVISIONS) ORDINANCE	106
INFORMATION ABOUT THIS PROSPECTUS AND THE GLOBAL OFFERING	115
DIRECTORS AND PARTIES INVOLVED IN THE GLOBAL OFFERING	119
CORPORATE INFORMATION	124

CONTENTS

INDUSTRY OVERVIEW	126
REGULATORY OVERVIEW	154
HISTORY, REORGANIZATION AND CORPORATE STRUCTURE	174
BUSINESS	188
RELATIONSHIP WITH OUR SINGLE LARGEST SHAREHOLDER	279
DIRECTORS AND SENIOR MANAGEMENT	283
SHARE CAPITAL	295
SUBSTANTIAL SHAREHOLDERS	298
FINANCIAL INFORMATION	301
FUTURE PLANS AND USE OF PROCEEDS	353
CORNERSTONE INVESTORS	355
UNDERWRITING	366
THE STRUCTURE OF THE GLOBAL OFFERING	379
HOW TO APPLY FOR HONG KONG OFFER SHARES	391
APPENDIX I ACCOUNTANT'S REPORT	I-1
APPENDIX II UNAUDITED PRO FORMA FINANCIAL INFORMATION	II-1
APPENDIX III PROFIT ESTIMATE	III-1
APPENDIX IV SUMMARY OF THE CONSTITUTION OF THE COMPANY AND CAYMAN COMPANY LAW	IV-1
APPENDIX V STATUTORY AND GENERAL INFORMATION	V-1
APPENDIX VI DOCUMENTS DELIVERED TO THE REGISTRAR OF COMPANIES IN HONG KONG AND AVAILABLE FOR INSPECTION	VI-1